JMP initiates ViroPharma at market outperform

ViroPharma Inc. coverage was initiated by JMP Securities LLC analyst Adam Cutler at a market outperform rating with a price target of $25. JMP said ViroPharma is a profitable, commercial-stage biotechnology company with sole product candidate Vancocin, which was acquired by Eli Lilly. JMP said it believes Vancocin will continue to drive sales growth and progress from the company's pipeline will drive appreciation for the stock. Shares of the Exton, Pa.-based pharmaceutical company were up $0.74, or 4.10%, at $18.80 on volume of 1,494,832 shares versus the three-month running average of 2,543,730 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.